GLEN ALLEN, Va., Feb. 12, 2014 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) announced today that Theodore Jenkins has joined the Company as Vice President, Corporate Strategy and Development. Mr. Jenkins will be working directly with Dr. Michael Mullan, Chairman and Chief Executive Officer, to enhance, broaden, and clarify the Company's institutional investment and corporate development efforts.
Mr. Jenkins' experience encompasses an extensive 18-year Wall Street career as an institutional capital markets professional, working at top-tier, global and regional investment banks. He has a proven history of generating significant client revenue and communicating differentiated value with some of the largest investment managers in the United States. He brings valuable insight, aptitude, and knowledge from working with a wide spectrum of biotech and pharmaceutical healthcare disciplines derived from his close interaction with numerous companies in the sector and with specialist healthcare finance professionals. As a result, Mr. Jenkins has an abundance of relationships across the institutional and corporate banking investment community.
Dr. Mullan commented, "I first met Ted a number of years ago and have been impressed with his business, technical, and scientific acumen, as it applies to the research and development strategy of the Company. His tireless enthusiasm and experience will be an invaluable asset for us."Mr. Jenkins' background includes nine years as a US Navy Officer serving as an aviator, flying F-14a tactical fighter aircraft and finishing his tour as a professional development instructor teaching midshipmen at the US Naval Academy in Annapolis, Maryland. He has a Master's of Science in Business from The Johns Hopkins University, and an undergraduate degree in International Studies from Washington College in Chestertown, Maryland. Mr. Jenkins can be reached by email for institutional and corporate inquiries at: email@example.com Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2012 and our quarterly reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013, and September 30, 2013. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. About Star Scientific